Wegovy Pill: Oral Semaglutide Complete Guide

Wegovy pill was FDA approved on December 22, 2025. It was the first oral GLP-1 medication approved specifically for weight loss in adults, a significant option for people who want the clinical benefits of semaglutide without weekly injections.

Here is a practical guide to what it is, how to take it, and how it compares to other options.

What is the Wegovy pill?

Wegovy pill contains oral semaglutide 25 mg, the same active molecule as Wegovy injection and Ozempic, but formulated as a once-daily tablet. It is approved for:

• weight reduction in adults with obesity (BMI ≥ 30)
• weight reduction in adults who are overweight (BMI ≥ 27) with at least one weight-related health condition
• reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity or overweight and established heart disease

As of October 2026, it is available in the United States through standard pharmacies, NovoCare direct pharmacy, and telehealth providers including Hims & Hers (under a March 2026 agreement with Novo Nordisk). Approval and availability in other countries differ, so check with your prescriber.

How does it work?

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut releases after eating, which:

• reduces appetite and food cravings
• slows gastric emptying (you feel full longer)
• improves insulin response
• signals the brain to reduce caloric intake

The oral formulation uses a co-formulation with a carrier molecule (SNAC) that helps semaglutide absorb through the stomach lining. This is why strict dosing rules are required.

How to take the Wegovy pill correctly

This is critical. Semaglutide does not absorb properly if taken incorrectly.

Rules for every dose:

1. Take in the morning on a completely empty stomach
2. Use no more than 120 ml (about half a cup) of plain water to swallow the tablet whole (do not split, crush or chew it)
3. Do not eat, drink anything other than water, or take other oral medications for at least 30 minutes after

If you miss a dose, the US label says to skip it and take the next dose the following day. Do not take more than one tablet a day.

Missing these rules significantly reduces how much semaglutide your body absorbs. This is the main practical difference from orforglipron, which has no food restrictions.

Dosing schedule

Wegovy pill uses a gradual escalation to reduce gastrointestinal side effects:

Full maintenance dose is reached after about 90 days. If a step is hard to tolerate, your prescriber may delay the next increase. Do not change your dose without your prescriber.

What weight loss can you expect?

The OASIS 4 Phase 3 trial (64 weeks, 307 adults with obesity, no diabetes) showed:

• 16.6% average weight loss if all patients stayed on treatment (vs 2.7% on placebo)
• 13.6% average weight loss counting everyone, whether or not they stayed on treatment (vs 2.4% on placebo in the FDA label analysis)
• 76% of patients achieved at least 5% weight loss vs 31% on placebo
• Baseline body weight: approximately 235 lbs (107 kg)

At that starting weight, 16.6% is roughly 39 lbs on average for patients who stay on the medication. Individual results vary.

Side effects

Side effects are the same as with the injectable form:

• Nausea: most common, especially during the escalation phase
• Diarrhea
• Vomiting
• Constipation
• Fatigue

For most patients, these are mild to moderate and improve over time. The gradual escalation schedule is designed specifically to reduce early side effects.

The Wegovy label also lists serious but less common risks: pancreatitis, gallbladder problems, kidney problems from dehydration, low blood sugar when combined with insulin or a sulfonylurea, worsening diabetic eye disease, serious allergic reactions, and depression or suicidal thoughts. It carries a boxed warning about thyroid C-cell tumours, and it should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Seek urgent help for severe stomach pain that does not go away (it may spread to your back), signs of a serious allergic reaction, or if you cannot keep fluids down. Tell your care team before surgery or sedation, and stop at least 2 months before a planned pregnancy (discuss this with your prescriber).

Wegovy pill vs Wegovy injection

For patients comfortable with injections, the weekly shot may actually be easier to manage day-to-day, no morning dosing rules. For patients who want to avoid injections entirely, the pill is now a viable option.

Wegovy pill vs Orforglipron

Both are daily oral GLP-1 medications, but they differ in an important way.

Orforglipron (Eli Lilly, FDA approved as Foundayo on April 1, 2026) is a non-peptide small molecule: it does not require food restrictions. You can take it at any time, with or without food. The Wegovy pill requires fasting and a 30-minute wait.

In the ACHIEVE-3 head-to-head trial, orforglipron produced significantly more weight loss than a 14 mg dose of oral semaglutide in T2D patients. But the Wegovy pill is approved at 25 mg, which is much higher than the 14 mg dose used in that comparison.

Tracking the Wegovy pill

Switching from an injection to a daily pill changes your tracking pattern. Instead of a weekly injection day as your anchor, you are logging a daily routine. The dosing rules, empty stomach, timing, are important to track consistently, especially during the escalation phase when missing doses can affect side effect patterns.

Weight Easy supports all semaglutide formulations and helps you track dose changes, side effects, and weight trends across the escalation period.

Final takeaway

Wegovy pill is a once-daily oral semaglutide approved in the US in December 2025 for weight loss in adults with obesity or overweight. In its main trial it produced weight loss broadly similar to the weekly injection's trials but requires strict morning dosing rules. It is a meaningful option for patients who prefer tablets over injections.

Consult your healthcare provider before starting any weight loss medication.

Consult your healthcare provider before starting any medication.

Sources

• Rybelsus prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf
• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• MedlinePlus — semaglutide: https://medlineplus.gov/druginfo/meds/a618008.html
• MedlinePlus — semaglutide tablets: https://medlineplus.gov/druginfo/meds/a619057.html

Related Articles

• Wegovy HD (High Dose): What You Need to Know

• Orforglipron: The First Oral GLP-1 Pill

• Ozempic and Wegovy Price Drop 2027: What to Expect

• Wegovy (injection and tablets) prescribing information, U.S. FDA, revised 12/2025: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf

• OASIS 4 trial: Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969

• Novo Nordisk / Hims & Hers company statement, March 9, 2026: https://www.novomedlink.com/content/dam/novomedlink/semaglutide/03-09-2026-company-statement.pdf

• Foundayo (orforglipron) FDA approval package, April 1, 2026: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220934Orig1s000Approv.pdf